{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Sexually+Transmitted+Diseases%2C+Viral&page=35", "query": { "condition": "Sexually Transmitted Diseases, Viral", "page": 35 }, "page_size": 10 }, "pagination": { "page": 35, "page_size": 10, "total_count": 3870, "total_pages": 387, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Sexually+Transmitted+Diseases%2C+Viral&page=36&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Sexually+Transmitted+Diseases%2C+Viral&page=34&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-17T12:58:57.327Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00038220", "title": "Effectiveness of ABT-378/Ritonavir Plus Lamivudine Plus Efavirenz Plus Tenofovir DF in HIV-Infected Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "Lopinavir/ritonavir", "type": "DRUG" }, { "name": "Efavirenz", "type": "DRUG" }, { "name": "Lamivudine", "type": "DRUG" }, { "name": "Tenofovir DF", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Abbott", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 40, "start_date": "2000-07", "completion_date": null, "has_results": false, "last_update_posted_date": "2006-07-27", "last_synced_at": "2026-10-17T12:58:57.327Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00038220" }, { "nct_id": "NCT03089320", "title": "Financial Incentives, Randomization With Stepped Treatment Trial", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Unhealthy Alcohol Use" ], "interventions": [ { "name": "Contingency Management Counseling", "type": "BEHAVIORAL" }, { "name": "Addiction Physician Management", "type": "BEHAVIORAL" }, { "name": "Motivational Enhancement Therapy", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "Yale University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 120, "start_date": "2018-05-01", "completion_date": "2023-04-01", "has_results": true, "last_update_posted_date": "2024-04-15", "last_synced_at": "2026-10-17T12:58:57.327Z", "location_count": 7, "location_summary": "Los Angeles, California • Washington D.C., District of Columbia • Atlanta, Georgia + 4 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "New Orleans", "state": "Louisiana" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03089320" }, { "nct_id": "NCT02411435", "title": "Effect of Rifampin (RIF) on the Pharmacokinetics (PK) of Oral Cabotegravir (CAB) in Healthy Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Infection, Human Immunodeficiency Virus" ], "interventions": [ { "name": "CAB", "type": "DRUG" }, { "name": "RIF", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ViiV Healthcare", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 15, "start_date": "2015-07", "completion_date": "2015-09", "has_results": false, "last_update_posted_date": "2016-01-06", "last_synced_at": "2026-10-17T12:58:57.327Z", "location_count": 1, "location_summary": "Overland Park, Kansas", "locations": [ { "city": "Overland Park", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02411435" }, { "nct_id": "NCT05026723", "title": "Food as Medicine for HIV and Diabetes", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Diabetes Mellitus, Type 2", "HIV Infections", "PreDiabetes" ], "interventions": [ { "name": "MTM + ILI", "type": "BEHAVIORAL" }, { "name": "Standard MTM", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "University of North Carolina, Chapel Hill", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 200, "start_date": "2021-10-04", "completion_date": "2027-04", "has_results": false, "last_update_posted_date": "2026-09-01", "last_synced_at": "2026-10-17T12:58:57.327Z", "location_count": 1, "location_summary": "Chapel Hill, North Carolina", "locations": [ { "city": "Chapel Hill", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT05026723" }, { "nct_id": "NCT00046176", "title": "A HIV Study Of A Fixed-Dose Combination Tablet In Antiretroviral Experienced Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Infection, Human Immunodeficiency Virus I", "HIV Infection" ], "interventions": [ { "name": "abacavir/lamivudine", "type": "DRUG" }, { "name": "abacavir", "type": "DRUG" }, { "name": "lamivudine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ViiV Healthcare", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 240, "start_date": "2002-08-26", "completion_date": "2004-05-17", "has_results": false, "last_update_posted_date": "2020-03-24", "last_synced_at": "2026-10-17T12:58:57.327Z", "location_count": 52, "location_summary": "Phoenix, Arizona • Fountain Valley, California • Long Beach, California + 34 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Long Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00046176" }, { "nct_id": "NCT00055185", "title": "Safety and Efficacy of PRO 542 in the Treatment of HIV-Infected Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HIV Infections", "Acquired Immune Deficiency Syndrome" ], "interventions": [ { "name": "CD4-IgG2 (PRO 542)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Progenics Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 24, "start_date": "2003-04", "completion_date": "2005-06", "has_results": false, "last_update_posted_date": "2008-10-03", "last_synced_at": "2026-10-17T12:58:57.327Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00055185" }, { "nct_id": "NCT02573376", "title": "Antiviral Pharmacology and Adherence in Drug Users", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "HEPATITIS C", "Virus, Human Immunodeficiency" ], "interventions": [ { "name": "Directly Observed Therapy", "type": "BEHAVIORAL" }, { "name": "Wirelessly Observed Therapy", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "University of Colorado, Denver", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 73, "start_date": "2015-11", "completion_date": "2021-06", "has_results": false, "last_update_posted_date": "2022-03-08", "last_synced_at": "2026-10-17T12:58:57.327Z", "location_count": 1, "location_summary": "Aurora, Colorado", "locations": [ { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT02573376" }, { "nct_id": "NCT00052182", "title": "Safety of and Immune System Response to an HIV Vaccine (EP HIV-1090) in HIV Infected Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "EP HIV-1090", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "59 Years", "sex": "ALL", "summary": "18 Years to 59 Years" }, "enrollment_count": 40, "start_date": "2002-10", "completion_date": null, "has_results": false, "last_update_posted_date": "2007-10-23", "last_synced_at": "2026-10-17T12:58:57.327Z", "location_count": 1, "location_summary": "Denver, Colorado", "locations": [ { "city": "Denver", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT00052182" }, { "nct_id": "NCT05592626", "title": "A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Solid Tumors", "Genital Neoplasm, Female", "Urogenital Neoplasms", "Lung Neoplasm", "Neoplasms by Site", "Papillomavirus Infection", "Epstein-Barr Virus Infections", "Carcinoma", "Neoplasms", "Vulvar Neoplasms", "Vulvar Diseases", "Abdominal Neoplasm", "NSCLC (Non-small Cell Lung Cancer)", "Colorectal Cancer" ], "interventions": [ { "name": "STAR0602", "type": "DRUG" }, { "name": "Irinotecan (Camptosar)", "type": "COMBINATION_PRODUCT" }, { "name": "Docetaxel (Taxotere)", "type": "COMBINATION_PRODUCT" } ], "intervention_types": [ "DRUG", "COMBINATION_PRODUCT" ], "sponsor": "Marengo Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 366, "start_date": "2023-01-04", "completion_date": "2027-09", "has_results": false, "last_update_posted_date": "2026-08-11", "last_synced_at": "2026-10-17T12:58:57.327Z", "location_count": 13, "location_summary": "Sacramento, California • Celebration, Florida • Miami, Florida + 10 more", "locations": [ { "city": "Sacramento", "state": "California" }, { "city": "Celebration", "state": "Florida" }, { "city": "Miami", "state": "Florida" }, { "city": "Kansas City", "state": "Kansas" }, { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT05592626" }, { "nct_id": "NCT05241990", "title": "Practice Facilitation as a Strategy to Improve Alcohol Treatment Adoption and Implementation in HIV Care", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Hiv", "Alcohol Use, Unspecified" ], "interventions": [ { "name": "Practice Facilitation", "type": "BEHAVIORAL" }, { "name": "Alcohol Stepped Care", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "Johns Hopkins University", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 300, "start_date": "2023-02-15", "completion_date": "2027-09-30", "has_results": false, "last_update_posted_date": "2026-06-26", "last_synced_at": "2026-10-17T12:58:57.327Z", "location_count": 3, "location_summary": "San Diego, California • Boston, Massachusetts • Chapel Hill, North Carolina", "locations": [ { "city": "San Diego", "state": "California" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Chapel Hill", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT05241990" } ] }